Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.03 AUD
Change Today 0.00 / 0.00%
Volume 140.5K
ACL On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Frankfurt
As of 12:48 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

alchemia ltd (ACL) Snapshot

Open
A$0.03
Previous Close
A$0.03
Day High
A$0.03
Day Low
A$0.03
52 Week High
09/11/14 - A$0.68
52 Week Low
06/30/15 - A$0.03
Market Cap
10.7M
Average Volume 10 Days
334.4K
EPS TTM
A$-0.05
Shares Outstanding
324.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALCHEMIA LTD (ACL)

Related News

No related news articles were found.

alchemia ltd (ACL) Related Businessweek News

No Related Businessweek News Found

alchemia ltd (ACL) Details

Alchemia Limited, a biotechnology company, engages in developing human therapeutic products based on its proprietary drug discovery and synthesis technologies in Australia and the United States. The company operates through Fondaparinux and HyACT segments. It provides generic Fondaparinux, an injectable anticoagulant drug for the prevention and treatment of deep vein thrombosis and pulmonary embolism. The company also offers HyACT, a platform technology that uses the non-toxic and naturally occurring carbohydrate, hyaluronic acid as a drug delivery vehicle for a range of approved anti-cancer therapeutics. In addition, it is developing HA-Irinotecan that is in the Phase II clinical trials for the treatment of small cell lung cancer. The company has collaboration agreement with Merck Serono to develop HA-Irinotecan in combination with therapeutic antibody, Erbitux (cetuximab), for patients with metastatic colorectal cancer. Alchemia Limited was founded in 1995 and is headquartered in Brisbane, Australia.

Founded in 1995

alchemia ltd (ACL) Top Compensated Officers

Chief Financial Officer and Company Secretary
Total Annual Compensation: A$239.8K
Chief Scientific Officer and Vice President o...
Total Annual Compensation: A$225.4K
Group Financial Controller
Total Annual Compensation: A$180.0K
Vice President of Drug Discovery
Total Annual Compensation: A$214.7K
Vice President of Intellectual Property & Tec...
Total Annual Compensation: A$208.9K
Compensation as of Fiscal Year 2015.

alchemia ltd (ACL) Key Developments

Alchemia Limited Announces Cash Flow Results for the Fourth Quarter Ended June 30, 2015

Alchemia Limited announced cash flow results for the fourth quarter ended June 30, 2015. The company reported a net operating cash outflow of $5.6 million for the quarter ended 30 June 2015. This quarter's net cash burn includes close out of many contracts for the Phase III trial for HA-Irinotecan.

Alchemia Limited to Report Fiscal Year 2015 Results on Aug 28, 2015

Alchemia Limited announced that they will report fiscal year 2015 results at 11:08 PM, GMT Standard Time on Aug 28, 2015

Alchemia Limited Announces Board Appointments

Alchemia Limited announced the appointment of Mr. Ken Poutakidis as interim chairman of the board of directors. Mr. Nathan Drona has been appointed as chairman of the audit, compliance and risk committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACL:AU A$0.03 AUD 0.00

ACL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACL.
View Industry Companies
 

Industry Analysis

ACL

Industry Average

Valuation ACL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALCHEMIA LTD, please visit www.alchemia.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.